Abstract

Inspired by the success of fluorinated corticosteroids in the 1950s and fluoroquinolones in the 1980s, fluorine-containing pharmaceuticals, which are also known as fluoro-pharmaceuticals, have been attracting attention for more than half of a century. Presently, about 20% of the commercial pharmaceuticals are fluoro-pharmaceuticals. In this mini-review, we analyze the prevalence of fluoro-pharmaceuticals in the market and categorize them into several groups based on the chemotype of the fluoro-functional groups, their therapeutic purpose, and the presence of heterocycles and/or chirality to highlight the structural motifs, patterns, and promising trends in fluorine-based drug design. Our database contains 340 fluoro-pharmaceuticals, from the first fluoro-pharmaceutical, Florinef, to the latest fluoro-pharmaceuticals registered in 2019 and drugs that have been withdrawn. The names and chemical structures of all the 340 fluorinated drugs discussed are provided in the Supporting Information.

Keywords

DrugChemistryCombinatorial chemistryPharmacologyMedicine

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
review
Volume
5
Issue
19
Pages
10633-10640
Citations
1655
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1655
OpenAlex
5
Influential
1590
CrossRef

Cite This

Munenori Inoue, Yuji Sumii, Norio Shibata (2020). Contribution of Organofluorine Compounds to Pharmaceuticals. ACS Omega , 5 (19) , 10633-10640. https://doi.org/10.1021/acsomega.0c00830

Identifiers

DOI
10.1021/acsomega.0c00830
PMID
32455181
PMCID
PMC7240833

Data Quality

Data completeness: 86%